Zentek

Zentek has announced the completion of the Innovative Solutions Canada - Testing Stream contract for ZenARMOR™ nano-pigment in military grade, chromate-free corrosion protection aerospace paint systems, and a new collaboration with Jazeera Paints Company for continued product development and testing.

ZenARMOR™ was evaluated in commercial non-chromate aviation paint systems developed by PPG and Akzo Nobel. Three rounds of corrosion testing were completed from September 2023 to July 2024 and testing followed ASTM B117 (salt spray) and ASTM D5894 (cyclical corrosion) standards. The tests were reportedly successful in demonstrating the effectiveness of ZenARMOR™ nano-pigments in inhibiting corrosion of the aluminum alloy AA2024-T3.

Zentek has announced the signing of a collaboration agreement (effective April 11, 2025) with Filtration Solutions Industrial Co. (“FSCO”), a leading Saudi-based manufacturer and distributor of air filtration products, to manufacture and distribute ZenGUARD™ Enhanced Air Filters across the Gulf Cooperation Council (“GCC”) region.

Under the terms of the agreement, Zentek will supply FSCO with HVAC filter media coated with its proprietary graphene-silver-based ZenGUARD™ technology — known for its ability to significantly increase viral filtration efficiency. FSCO will produce ZenGUARD™ Enhanced Air Filters that will be marketed and distributed under Zentek’s branding throughout the GCC, including Saudi Arabia, the United Arab Emirates, Kuwait, Qatar, Bahrain, and Oman, with the net revenue generated from sales of the products shared between Zentek and FSCO. The term of the agreement is for three years, with additional renewal options.

Zentek has announced that it has closed a non-brokered private placement (the “Offering”) of debenture units for gross proceeds of CAD$2,000,000 (around US$1,442,000).  

Net proceeds from this offering will be used for working capital and general corporate purposes.  

Zentek has announced it has entered into an at-the-market offering agreement (the “ATM Agreement”), to raise gross proceeds of up to US$30 million. Rodman & Renshaw LLC is acting as the exclusive sales agent for the Offering.

Sales of Common Shares will be made through an "at-the-market offering", made directly on the Nasdaq Capital Markets (“Nasdaq”), or any other recognized marketplace on which the Common Shares are listed, quoted or traded in the United States or through a market maker. No offers or sales of Common Shares will be made in Canada on the TSX Venture Exchange or other trading markets in Canada.

Zentek has announced a strategic partnership with Al-Ramez International Group, facilitated through Saudi Excellence Holding Company. The partnership aims to foster innovation and commercialization of advanced technologies in the Kingdom of Saudi Arabia (KSA) and the Middle East and North Africa (MENA) region.

Under the Memorandum of Understanding (MOU), Zentek will contribute its intellectual property, product licensing, and research and development expertise. In turn, Al-Ramez International Group will provide marketing support, investor relations, financing, and market access within KSA and MENA. The collaboration seeks to achieve several objectives, including the development of a graphene production facility in KSA, a commercialization hub for Zentek's graphene technologies, and the expansion of biotechnology research. The agreement also aims to secure strategic investment in resources to support the North American supply chain for advanced materials and establish a research and development center for aptamer technology in conjunction with a Saudi university.

Zentek has announced that its wholly-owned subsidiary Triera Biosciences has received a CAD$1.1 million (around USD$791,000) Government of Canada contract to test its multivalent aptamer technology for the rapid drug discovery of therapeutics or prophylactics of highly pathogenic avian influenza (“HPAI”) A(H5N1).

Triera was awarded a these funds through Innovation, Science and Economic Development Canada's (“ISED”) Innovative Solutions Canada (“ISC”) program: Health Advanced And Emerging Medical Technologies. Triera’s multivalent aptamer technology was selected for its potential to be used as a rapid drug development platform.

Zentek has provided an update on recent commercialization activities for its ZenGUARD™ Antimicrobial Surgical Masks.

As previously announced in July 2024, the Company embarked on a Canada-wide sampling program for dental professionals facilitated by Henry Schein Inc. that saw ZenGUARD™ Antimicrobial Surgical Masks included in product shipments to Henry Schein customers across Canada. As a result of this program, the Company is now reportedly seeing increased demand from Henry Schein, the world’s largest provider of health care solutions to office-based dental and medical practitioners with a presence in 33 countries.

Zentek has announced that it has closed its non-brokered private placement for gross proceeds of CAD$3,069,950 (around USD$2,254,000). Net proceeds of the Offering will be used for working capital and general corporate purposes.

Zentek's CEO, Greg Fenton, commented: "We would like to thank all those who participated in the Offering. This funding will allow us to immediately allocate resources to our international market expansion strategy, where ZenGUARD-coated HVAC filters can play a meaningful role in an entity's sustainability objectives."

Zentek has reported its earnings for the first quarter ended June 30, 2024. For the first quarter, the Company reported sales was CAD 0.005489 million (USD$0.004). Net loss was CAD 2.55 million (around USD$1,857,000) compared to CAD 3.16 million (around USD$2,300,000) a year ago.

Basic loss per share from continuing operations was CAD 0.03 compared to CAD 0.03 a year ago. Diluted loss per share from continuing operations was CAD 0.03 compared to CAD 0.03 a year ago.

Zentek has announced that it will embark on a Canada-wide sampling program for dental professionals facilitated by Henry Schein that will see ZenGUARD™ Antimicrobial Surgical Masks included in product shipments to Henry Schein customers.

In addition to offering dental practitioners and their patients a surgical mask with improved protection against infectious agents, ZenGUARD™ Antimicrobial Surgical Masks are also said to be proven to eliminate 99.9% of bacteria, which can collect on the skin when wearing a surgical mask for extended periods and cause acne. The Company believes this program will introduce ZenGUARD™ Antimicrobial Surgical Masks and this unique value proposition to nearly all Henry Schein customers across Canada.